Gary P Jeffrey
Overview
Explore the profile of Gary P Jeffrey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
1500
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
22.
Jeffrey A, Jeffrey G, Stormon M, Thomas G, OLoughlin E, Shun A, et al.
Med J Aust
. 2020 Oct;
213(10):464-470.
PMID: 33015834
Objective: To assess long term graft and patient survival after donor liver retransplantation in children in Australia and New Zealand during 1986-2017; to determine the factors that influence survival. Design:...
23.
Calzadilla-Bertot L, Vilar-Gomez E, Wong V, Romero-Gomez M, Aller-de la Fuente R, Wong G, et al.
Hepatology
. 2020 Sep;
73(6):2238-2250.
PMID: 32978796
Background And Aims: Nonalcoholic fatty liver disease (NAFLD) is an increasingly important cause of liver cirrhosis and subsequent complications. We retrospectively developed and validated a model to predict hepatic decompensation...
24.
Drak D, Tangirala N, Fink M, Adams L, Fawcett J, Jeffrey G, et al.
Transplant Proc
. 2020 Sep;
53(1):136-140.
PMID: 32933766
Aim: Rates of simultaneous liver and kidney transplantation (SLKT) have increased, but indications for SLKT remain poorly defined. Additional data are needed to determine which patients benefit from SLKT to...
25.
Adams L, Wang Z, Liddle C, Melton P, Ariff A, Chandraratna H, et al.
Liver Int
. 2020 Apr;
40(6):1356-1365.
PMID: 32243703
Background: Bile acids (BAs) are synthesized by the liver and modified by gut bacteria, and may play an intermediary role between the gut microbiome and liver in promoting fibrosis in...
26.
Jeffrey G, Gordon L, Ramm G
Med J Aust
. 2020 Feb;
212(7):297-299.e1.
PMID: 32092155
No abstract available.
27.
Wallace M, Samuelson S, Khoo T, Ooi J, Tibballs J, Ferguson J, et al.
J Gastroenterol Hepatol
. 2020 Feb;
35(11):1945-1952.
PMID: 32036614
Background And Aim: Yttrium-90 resin microsphere radioembolization (RE) is not recommended for routine use in intermediate or advanced hepatocellular carcinoma (HCC) by recent guidelines. This study aims to establish pre-treatment...
28.
Jeffrey G, Gordon L, Hill M, Ramm G
Hepatology
. 2020 Feb;
71(6):2160-2162.
PMID: 32031686
No abstract available.
29.
Koshy A, Gow P, Han H, Teh A, Jones R, Testro A, et al.
Eur Heart J Qual Care Clin Outcomes
. 2020 Feb;
6(4):243-253.
PMID: 32011663
Aims: There has been significant evolution in operative and post-transplant therapies following liver transplantation (LT). We sought to study their impact on cardiovascular (CV) mortality, particularly in the longer term....
30.
Jeffrey A, Delriviere L, McCaughan G, Crawford M, Angus P, Jones R, et al.
Transplant Direct
. 2019 Oct;
5(8):e472.
PMID: 31576368
Background: Liver retransplantation is technically challenging, and historical outcomes are significantly worse than for first transplantations. This study aimed to assess graft and patient survival in all Australian and New...